Trial Profile
Retrospective analysis of metastatic colorectal cancer (mCRC) patients treated with Bevacizumab/Tyrosine kinase inhibitor investigating hypertension and proteinuria as markers of efficacy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Dec 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Protein tyrosine kinase inhibitors (Primary)
- Indications Colorectal cancer
- Focus Pharmacodynamics; Therapeutic Use
- 17 Dec 2015 New trial record